EFFICACY AND SAFETY OF A TARGETED-RELEASE FORMULATION OF BUDESONIDE (HR19042 CAPSULES) IN PATIENTS WITH PRIMARY IgA NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2/3 TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
EFFICACY AND SAFETY OF A TARGETED-RELEASE FORMULATION OF BUDESONIDE (HR19042 CAPSULES) IN PATIENTS WITH PRIMARY IgA NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2/3 TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Xiaobing
Yang
Xiaobing Yang yxb7829@163.com Nanfang Hospital Southern Medical University National Clinical Research Center for Kidney Disease Guangzhou China *
Wei Chen vvchen66@qq.com The First Affiliated Hospital, Sun Yat‑sen University Department of Nephrology Guangzhou China -
Lihua Wang lihuawang236@126.com Second Hospital of Shanxi Medical University Nephrology Taiyuan China -
Jun Xue xuejun@fudan.edu.cn Huashan Hospital, Fudan University Department of Nephrology Shanghai China -
Leyi Gu guleyi@aliyun.com Renji Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine Department of Nephrology Shanghai China -
Wenxiu Chang changwx@sina.com Tianjin First Central Hospital Department of Nephrology Tianjin China -
Gang Xu gangxu99@163.com Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology Department of Nephrology Wuhan China -
Bicheng Liu liubc64@163.com Zhongda Hospital, Southeast University Department of Nephrology Nanjing China -
Liang Wang wangliang_wuxi@126.com Wuxi City People's Hospital Department of Nephrology Wuxi China -
Ping Luo luopingjen@163.com The Second Hospital of Jilin University Department of Nephrology Changchun China -
Rong Wang wrjlsd@163.com Shandong Provincial Hospital Department of Nephrology Jinan China -
Su Zhang su.zhang.sz3@hengrui.com Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Research & Development Shanghai China -
Rong Huang rong.huang@hengrui.com Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Research & Development Shanghai China -
Fanfan Hou ffhouguangzhou@163.com Nanfang Hospital Southern Medical University National Clinical Research Center for Kidney Disease Guangzhou China -